The use of CA125 as a serum monitor continues to be the gold standard; however, ctDNA alone, or in combination with protein biomarkers, has recently emerged as a more specific and sensitive biomarker combination for the monitoring and detection of early recurrence in ovarian cancer patients. This evidence concerns the gene MUC16 and ovarian cancer.